Qiagen NV (XTER:QIA) EBIT: €424 Mil (TTM As of Mar. 2026)


XTER:QIA Qiagen NV XTER:QIA
71 GF Score
Price €34.57
GF Value €45.90
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Qiagen NV EBIT?

Qiagen NV XTER:QIA +0.74% 71 EBIT is €424 Mil as of Mar. 2026. GuruFocus rates XTER:QIA with a GF Score™ of 71/100 and a GF Value™ of €45.90 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Qiagen NV's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €84 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €424 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Qiagen NV's annualized ROC % for the quarter that ended in Mar. 2026 was 7.81%. Qiagen NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 28.87%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Qiagen NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.24%.


Qiagen NV  (XTER:QIA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Qiagen NV's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=403.524 * ( 1 - 20.72% )/( (4161.273 + 4028.016)/ 2 )
=319.9138272/4094.6445
=7.81 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5364.172 - 264.423 - ( 938.476 - max(0, 437.365 - 1703.792+938.476))
=4161.273

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5001.486 - 414.43 - ( 559.04 - max(0, 414.43 - 1332.32+559.04))
=4028.016

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Qiagen NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=335.204/( ( (919.837 + max(252.297, 0)) + (791.292 + max(358.85, 0)) )/ 2 )
=335.204/( ( 1172.134 + 1150.142 )/ 2 )
=335.204/1161.138
=28.87 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(343.827 + 257.812 + 63.396) - (264.423 + 67.827 + 80.488)
=252.297

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(343.073 + 267.809 + 162.398) - (414.43 + 0 + 0)
=358.85

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Qiagen NV's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=424.025/8084.784
=5.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qiagen NV EBIT Related Terms


Qiagen NV EBIT Historical Data

* Premium members only.

The historical data trend for Qiagen NV's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qiagen NV EBIT Chart

Qiagen NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 602.07 538.98 443.11 157.56 447.09

Qiagen NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 117.33 116.55 121.79 101.89 83.80

XTER:QIA vs TWST, CRL, BLLN: EBIT Comparison

For the Diagnostics & Research subindustry, Qiagen NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qiagen NV EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Qiagen NV's EV-to-EBIT falls into.


XTER:QIA
71GF Score
Qiagen NV XTER:QIA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Qiagen NV EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €424 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €424 Mil mean?
Qiagen NV (XTER:QIA) has a EBIT of €424 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Qiagen NV.
Is Qiagen NV's EBIT too high?
Qiagen NV's current EBIT is €424 Mil. Overall, Qiagen NV has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qiagen NV's EBIT compare to TWST and CRL?
Qiagen NV's EBIT of €424 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Qiagen NV. Qiagen NV's current EBIT is €424 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qiagen NV stock overvalued right now?
Based on GuruFocus' analysis, Qiagen NV (XTER:QIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €45.90, compared to a current price of €34.57 — trading 24.7% below its estimated fair value. The current EBIT is €424 Mil. Qiagen NV's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Qiagen NV (XTER:QIA), the current EBIT is €424 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Qiagen NV (XTER:QIA) Overvalued in 2026?

Based on GuruFocus' analysis, Qiagen NV stock appears to be undervalued. The current stock price of €34.57 is trading 24.7% below its estimated GF Value™ of €45.90. GuruFocus considers Qiagen NV to be Modestly Undervalued.

Key valuation signals for XTER:QIA:

  • EBIT: €424 Mil
  • GF Value™: €45.90 vs. price of €34.57 (24.7% below fair value)
  • GF Score™: 71/100 with 2 warning signs

No single metric tells the full story. See the XTER:QIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Qiagen NV Business Description

Address Hulsterweg 82, Venlo, LI, NLD, 5912 PL
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
71GF Score

Get the complete analysis for XTER:QIA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€34.57
Price
€45.90
GF Value